Evaluating the importance of HER2 biomarker performance in diagnosing and relating it to other clinical factors in women with breast cancer referring to the Besat Clinic

Ansar  Karimian; Shima Shams; Morteza Rahbar-Taramsari; Seyed Hossein Mirpour Hassan Kiadeh; Seyedeh Elham Norollahi; Kosar Babaei; Ali Davoudi kiakalayeh; Ali Akbar Samadani

Koomesh

Journal of Semnan University of Medical Sciences

Current Issue Archive In Press Accepted Manuscripts Search

Journal Information Editors & Boards Indexing and Listing Sources Journal Metrics Open Peer Review (OPR)Publication Ethics and Publication Malpractice Statement Support Contact Us Reviewer and AE Registration Form

APC

Authors Guide Submit Manuscript

Evaluating the importance of HER2 biomarker performance in diagnosing and relating it to other clinical factors in women with breast cancer referring to the Besat Clinic

Author(s):

Ansar Karimian,

Shima Shams,

Morteza Rahbar-Taramsari,

Seyed Hossein Mirpour Hassan Kiadeh,

Seyedeh Elham Norollahi,

Kosar Babaei,

Ali Davoudi kiakalayeh,

Ali Akbar Samadani

^,*

Koomesh:Vol. 25, issue 3; 299-308

Published online:Aug 07, 2023

Article type:Research Article

Received:Feb 02, 2023

Accepted:Aug 07, 2023

How to Cite:Ansar KarimianShima ShamsMorteza Rahbar-TaramsariSeyed Hossein Mirpour Hassan KiadehSeyedeh Elham NorollahiKosar BabaeiAli Davoudi kiakalayehAli Akbar Samadaniet al.Evaluating the importance of HER2 biomarker performance in diagnosing and relating it to other clinical factors in women with breast cancer referring to the Besat Clinic.koomesh.25(3):e152828.

Abstract

Introduction: Breast cancer is one of the most common cancers in women and the second leading cause of death from cancer in women aged 20-59. Correspondingly, tumor markers such as HER-2/neu and PR ER P53 can be used to determine the severity of the disease and how to treat these patients. The purpose of this study was to investigate the importance of HER-2 biomarker function in diagnosis and its relationship with other clinical factors in women with breast cancer. Materials and Methods: This cross-sectional-analytical study included all breast cancer patients who were referred to Rasht's Besat Clinic between 2018 and 2019, and their breast cancer was confirmed by pathology results. The CVR coefficient was obtained for each question (-0.8 to 1) and the CVI index was above 80%. HER-2 biomarker status was recorded in immunohistochemical evaluation. Results: In this study, there is also a significant relationship between HER-2 biomarkers with the age of diagnosis, place of residence, marital status, education, exercise frequency, menstrual cycle, age at first menstruation, age at first live birth, history of abortion, history of Breastfeeding, history of the contraceptive hormone, history of smoking, alcohol, drugs, history of breast cancer and non-breast cancer in first and second degree relatives, history of HPV, history of metastasis was not found. A significant correlation was found between HER-2 biomarker and weight, age of first pregnancy, and the number of children. Conclusion: Based on the results of this study, the expression of HER-2 biomarkers in breast cancer patients increases with increasing weight, increasing the age of patients, and decreasing the number of children.

Keywords

References

1.
Blasco-Benito S, Moreno E, Seijo-Vila M, Tundidor I, Andradas C, Caffarel MM, et al. Therapeutic targeting of HER2-CB2R heteromers in HER2-positive breast cancer. Proc Natl Acad Sci U S A 2019; 116: 3863-3872.
2.
Mohammadbeigi A, Mohammadsalehi N, Valizadeh R, Momtaheni Z, Mokhtari M, Ansari H. Lifetime and 5 years risk of breast cancer and attributable risk factor according to Gail model in Iranian women. J Pharm Bioallied Sci 2015; 7: 207.
3.
Haghighat S, Omidi Z, Ghanbari-Motlagh A. Trend of breast cancer incidence in Iran during a fifteen-year interval according to national cancer registry reports. Iran J Breast Dis 2022; 15: 4-17.##https://doi.org/10.30699/ijbd.15.2.4.
4.
Makanjuola D, Alkushi A, Alzaid M, Abukhair O, Al Tahan F, Alhadab A. Breast cancer in women younger than 30 years: prevalence rate and imaging findings in a symptomatic population. Pan Afr Med J 2014; 19.
5.
Cerhan JR, Sellers TA, Janney CA, Pankratz VS, Brandt KR, Vachon CM. Prenatal and perinatal correlates of adult mammographic breast density. Cancer Epidemiol Biomarkers Prev 2005; 14: 1502-1508.
6.
Merklinger-Gruchala A, Ellison PT, Lipson SF, Thune I, Jasienska G. Low estradiol levels in women of reproductive age having low sleep variation. Eur J Cancer Prev 2008; 467-472.
7.
Shah AN, Gradishar WJ. Adjuvant anthracyclines in breast cancer: what is their role? The Oncologist 2018; 23: 1153-1161.
8.
Nguyen TH, Nguyen VH, Nguyen TL, Qiuyin C, Phung TH. Evaluations of biomarker status changes between primary and recurrent tumor tissue samples in breast cancer patients. Bio Med Res Int 2019; 2019.
9.
Dodson A, Parry S, Ibrahim M, Bartlett JM, Pinder S, Dowsett M, et al. Breast cancer biomarkers in clinical testing: analysis of a UK national external quality assessment scheme for immunocytochemistry and in situ hybridisation database containing results from 199 300 patients. J Pathol Clin Res 2018; 4: 262-273.
10.
Li J, Zhao B, Huang T, Qin Z, Wang SM. Human BRCA pathogenic variants were originated during recent human history. Life Sci Alliance 2022; 5.
11.
Anders CK, Johnson R, Litton J, Phillips M, Bleyer A, editors. Breast cancer before age 40 years. Seminars in oncology; 2009: Elsevier.
12.
Kang SY, Kim YS, Kim Z, Kim HY, Kim HJ, Park S, et al. Breast cancer statistics in Korea in 2017: data from a breast cancer registry. J Breast Cancer 2020; 23: 115.
13.
Miller AB. Final results of the UK Age trial on breast cancer screening age. Lancet Oncol 2020; 21: 1125-1126.
14.
White AJ, Bradshaw PT, Hamra GB. Air pollution and breast cancer: a review. Curr Epidemiol Rep 2018; 5: 92-100.
15.
Keramatinia A, Hassanipour S, Nazarzadeh M, Wurtz M, Monfared AB, Khayyamzadeh M, et al. Correlation between nitrogen dioxide as an air pollution indicator and breast cancer: a systematic review and meta-analysis. Asian Pac J Cancer Prev 2016; 17: 419-424.
16.
Inglis JE, Kleckner AS, Lin P-J, Gilmore NJ, Culakova E, VanderWoude AC, et al. Excess body weight and cancer-related fatigue, systemic inflammation, and serum lipids in breast cancer survivors. Nutr Cancer 2021; 73: 1676-1686.
17.
Dunneram Y, Greenwood DC, Cade JE. Diet, menopause and the risk of ovarian, endometrial and breast cancer. Proc Nutr Soc 2019; 78: 438-448.
18.
Nichols HB, Schoemaker MJ, Cai J, Xu J, Wright LB, Brook MN, et al. Breast cancer risk after recent childbirth: a pooled analysis of 15 prospective studies. Ann Int Med 2019; 170: 22-30.
19.
Power EJ, Chin ML, Haq MM. Breast cancer incidence and risk reduction in the Hispanic population. Cureus 2018; 10.##https://doi.org/10.7759/cureus.2235.
20.
Yeganeh Z, Sheikhan Z, Kariman N, Hajian P, Nasiri M, Mirzadeh N. Relationship between pregnancy-associated variables and breast cancer risk: A systematic review. Iran J Obstet Gynecol Infert 2018; 21: 85-97.
21.
Huang Y, Zhang X, Li W, Song F, Dai H, Wang J, et al. A meta-analysis of the association between induced abortion and breast cancer risk among Chinese females. Cancer Causes Control 2014; 25: 227-236.
22.
Deng Y, Xu H, Zeng X. Induced abortion and breast cancer: an updated meta-analysis. Medicine 2018; 97.
23.
Johnson HM, Mitchell KB. Breastfeeding and breast cancer: managing lactation in survivors and women with a new diagnosis. Ann Surg Oncol 2019; 26: 3032-3039.
24.
Darmon S, Park A, Lovejoy LA, Shriver CD, Zhu K, Ellsworth RE. Relationship between cigarette smoking and cancer characteristics and survival among breast cancer patients. Int J Environ Res Public Health 2022; 19: 4084.
25.
Butler EN, Tse CK, Bell ME, Conway K, Olshan AF, Troester MA. Active smoking and risk of Luminal and basal-like breast cancer subtypes in the carolina breast cancer study. Cancer Causes Control 2016; 27: 775-786.
26.
Baglia ML, Cook LS, MeiTzu C, Wiggins C, Hill D, Porter P, et al. Alcohol, smoking, and risk of H er2overexpressing and triplenegative breast cancer relative to estrogen receptorpositive breast cancer. Int J Cancer 2018; 143: 1849-1857.
27.
Reiner AS, Watt GP, John EM, Lynch CF, Brooks JD, Mellemkjr L, et al. Smoking, radiation therapy, and contralateral breast cancer risk in young women. J Natl Cancer Inst 2022; 114: 631-634.
28.
Sato A, Matsubayashi K, Morishima T, Nakata K, Kawakami K, Miyashiro I. Increasing trends in the prevalence of prior cancer in newly diagnosed lung, stomach, colorectal, breast, cervical, and corpus uterine cancer patients: a population-based study. BMC Cancer 2021; 21: 1-14.
29.
Kakugawa Y, Kawai M, Nishino Y, Fukamachi K, Ishida T, Ohuchi N, et al. Smoking and survival after breast cancer diagnosis in Japanese women: A prospective cohort study. Cancer Sci 2015; 106: 1066-1074.
30.
Li J, Ding J, Zhai K. Detection of human papillomavirus DNA in patients with breast tumor in China. PLoS One 2015; 10: e0136050.
31.
Islam MS, Chakraborty B, Panda CK. Human papilloma virus (HPV) profiles in breast cancer: future management. Ann Transl Med 2020; 8.

comments